- Home
- INNV vs ATXS Comparison
INNV vs ATXS Comparison
Compare INNV & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INNV
- ATXS
- Stock Information
- Founded
- INNV 2007
- ATXS 2008
- Country
- INNV United States
- ATXS United States
- Employees
- INNV N/A
- ATXS N/A
- Industry
- INNV Medical/Nursing Services
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- INNV Health Care
- ATXS Health Care
- Exchange
- INNV Nasdaq
- ATXS Nasdaq
- Market Cap
- INNV 485.4M
- ATXS 401.2M
- IPO Year
- INNV 2021
- ATXS 2015
- Fundamental
- Price
- INNV $3.43
- ATXS $6.85
- Analyst Decision
- INNV Sell
- ATXS Buy
- Analyst Count
- INNV 2
- ATXS 6
- Target Price
- INNV $5.00
- ATXS $32.00
- AVG Volume (30 Days)
- INNV 26.1K
- ATXS 248.4K
- Earning Date
- INNV 09-09-2025
- ATXS 08-12-2025
- Dividend Yield
- INNV N/A
- ATXS N/A
- EPS Growth
- INNV N/A
- ATXS N/A
- EPS
- INNV N/A
- ATXS N/A
- Revenue
- INNV $831,683,000.00
- ATXS N/A
- Revenue This Year
- INNV $13.77
- ATXS N/A
- Revenue Next Year
- INNV $10.12
- ATXS N/A
- P/E Ratio
- INNV N/A
- ATXS N/A
- Revenue Growth
- INNV 12.19
- ATXS N/A
- 52 Week Low
- INNV $2.60
- ATXS $3.56
- 52 Week High
- INNV $6.69
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- INNV 44.63
- ATXS 56.47
- Support Level
- INNV $3.18
- ATXS $6.60
- Resistance Level
- INNV $3.82
- ATXS $7.20
- Average True Range (ATR)
- INNV 0.27
- ATXS 0.47
- MACD
- INNV 0.01
- ATXS -0.03
- Stochastic Oscillator
- INNV 40.82
- ATXS 61.72
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.